Keros Therapeutics, INC

Keros Therapeutics provided an update on its investigational therapies, rinvatercept for neuromuscular disorders and elritercept for myelodysplastic syndromes, detailing clinical trial progress and preclinical findings.

Keros Therapeutics announced its second quarter 2026 financial results, highlighting a reduced net loss and the initiation of a Phase 2 clinical trial for rinvatercept in Duchenne muscular dystrophy patients.

Keros Therapeutics announced it will receive a $20 million development milestone payment from Takeda following the first patient dosing in the Phase 3 ELRiSE MDS clinical trial for elritercept.

Keros Therapeutics announced the resignation of CFO Keith Regnante, effective August 3, 2026, with Corporate Controller Annita Tanini stepping in as interim principal financial and accounting officer.

Keros Therapeutics has appointed Dr. Anne Prener, a veteran biopharmaceutical executive, to its Board of Directors effective July 1, 2026.

Keros Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Keros Therapeutics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing ongoing clinical development, financial performance, and risk factors.

Keros Therapeutics reports a net loss of $23.7 million for Q1 2026, a significant decrease from the prior year's net income, primarily due to the absence of a large upfront licensing payment.

Keros Therapeutics reported a net loss of $7.3 million for Q3 2025, alongside a $110.5 million net income for the nine months ended September 30, 2025, driven by the Takeda license agreement, and announced a $375 million capital return plan to stockholders.

Keros Therapeutics announced a significant net income for the first half of 2025 driven by a major licensing deal with Takeda, alongside a planned $375 million capital return to stockholders and a workforce reduction.

Keros Therapeutics reports a net income of $148.5 million for Q1 2025, primarily driven by revenue from its licensing agreement with Takeda, while advancing its clinical pipeline.

Keros Therapeutics reports a net loss of $53.0 million for the third quarter of 2024, while highlighting progress in its clinical programs for elritercept, cibotercept, and KER-065.

Keros Therapeutics achieved net income in 2025 driven by a Takeda licensing deal, while progressing lead candidates rinvatercept and elritercept, and executing a significant capital return program.

Keros Therapeutics reports its 2024 financial results, highlighting key clinical program advancements and a new licensing agreement with Takeda Pharmaceuticals.

Keros Therapeutics' 10-K filing outlines the details of its common stock, voting rights, dividend policies, and anti-takeover provisions, alongside updates on clinical trials and financial status.

Jean Jacques Bienaime, a Director of Keros Therapeutics, Inc., purchased 1,000 shares of common stock on July 15, 2026 for $10.61 per share.

Keros Therapeutics, Inc. reports that Director Anne Prener was granted restricted stock units and stock options on July 1, 2026.

Keros Therapeutics, Inc. reports that Director Jean Jacques Bienaime purchased 1,000 shares of common stock under a pre-arranged trading plan.

Director Nima Farzan sold 2,625 shares of Keros Therapeutics common stock via a pre-arranged 10b5-1 trading plan.

Keros Therapeutics Director Julius Knowles sold 2,625 shares of common stock for $10.73 per share under a pre-arranged trading plan.

Director Alpna Seth acquired 7,142 restricted stock units and 7,433 stock options in Keros Therapeutics, Inc.

Keros Therapeutics is holding its 2026 Annual Meeting of Stockholders on June 3, 2026, to elect directors, ratify auditors, and vote on executive compensation.

Leading independent proxy advisory firm Glass Lewis & Co. has recommended Keros Therapeutics stockholders vote FOR all three of the company's director nominees at the upcoming Annual Meeting, countering an activist campaign by ADAR1 Capital Management.

Keros Therapeutics is actively pursuing a strategic review to maximize stockholder value, while facing pressure from ADAR1 Capital, which the company claims is disruptive to the process.

Keros Therapeutics files investor presentation and issues open letter to stockholders, urging them to vote for the company's director nominees amidst a strategic review process and a campaign by ADAR1 Capital Management.

Keros Therapeutics issues a supplement to its proxy statement addressing a shareholder's intention to withhold votes for two director nominees ahead of the 2025 Annual Meeting.

Keros Therapeutics addresses concerns raised by ADAR1 Capital Management, defends its board nominees, and highlights its ongoing strategic review process.

Pontifax Parties sold their entire stake of 4.79 million Keros Therapeutics shares back to the company for $84.98 million, leading to board resignations.

Keros Therapeutics, Inc. has entered into a stock purchase agreement to repurchase 5,389,264 shares of its common stock from ADAR1 Capital Management and its affiliates for $95,659,436, as part of its previously announced $375 million Capital Return Program.

ADAR1 Capital Management, Keros Therapeutics' largest stockholder, is pressing the Board for engagement on strategy, capital allocation, and board refreshment, threatening a proxy fight.

ADAR1 Capital Management, Keros Therapeutics' largest shareholder, has publicly outlined proposals to maximize shareholder value, including business restructuring, cash returns, and optimizing the Takeda partnership, while announcing its intent to withhold votes for two current directors.

ADAR1 Capital Management, Keros Therapeutics' largest shareholder, has publicly criticized the company's capital allocation and strategic direction, announcing its intention to withhold votes for two directors and advocating for significant business restructuring.

ADAR1 Capital Management, the largest stockholder of Keros Therapeutics, Inc., has sent a letter to the Board of Directors demanding an immediate waiver or amendment of the annual meeting director nomination deadline, citing alleged breaches of fiduciary duties and actions taken to entrench current directors.

BlackRock, Inc. has reported beneficial ownership of 10.1% of Keros Therapeutics, Inc.'s common stock as of March 31, 2026.

The Vanguard Group reported 0% beneficial ownership in Keros Therapeutics Inc. following an internal realignment.

The Vanguard Group has reported a 5% beneficial ownership stake in Keros Therapeutics Inc., holding 1,525,355 shares of common stock.

ExodusPoint Capital Management, along with its affiliates, has reported a 6.3% beneficial ownership stake in Keros Therapeutics, Inc., totaling 1,907,899 shares.

D. E. Shaw & Co. entities and David E. Shaw have reported beneficial ownership of 5.1% of Keros Therapeutics, Inc.'s common stock.

Tang Capital Management and affiliated entities have reported a 7.9% passive ownership stake in Keros Therapeutics, Inc. as of October 15, 2025.